{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:00:30Z","timestamp":1762866030879},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"S1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Syst Biol"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Combination of different agents is widely used in clinic to combat complex diseases with improved therapy and reduced side effects. However, the identification of effective drug combinations remains a challenging task due to the huge number of possible combinations among candidate drugs that makes it impractical to screen putative combinations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In this work, we construct a 'drug cocktail network' using all the known effective drug combinations extracted from the Drug Combination Database (DCDB), and propose a network-based approach to investigate drug combinations. Our results show that the agents in an effective combination tend to have more similar therapeutic effects and share more interaction partners. Based on our observations, we further develop a statistical approach termed as DCPred (<jats:underline>D<\/jats:underline> rug <jats:underline>C<\/jats:underline> ombination <jats:underline>Pred<\/jats:underline> ictor) to predict possible drug combinations by exploiting the topological features of the drug cocktail network. Validating on the known drug combinations, DCPred achieves the overall AUC (Area Under the receiver operating characteristic Curve) score of 0.92, indicating the predictive power of our proposed approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The drug cocktail network constructed in this work provides useful insights into the underlying rules of effective drug combinations and offer important clues to accelerate the future discovery of new drug combinations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1752-0509-6-s1-s5","type":"journal-article","created":{"date-parts":[[2012,7,16]],"date-time":"2012-07-16T10:38:25Z","timestamp":1342435105000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The drug cocktail network"],"prefix":"10.1186","volume":"6","author":[{"given":"Ke-Jia","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangning","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,16]]},"reference":[{"key":"874_CR1","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1158\/1078-0432.CCR-1060-02","volume":"10","author":"A Argiris","year":"2004","unstructured":"Argiris A, Wang CX, Whalen SG, DiGiovanna MP: Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clinical Cancer Research. 2004, 10: 1409-1420. 10.1158\/1078-0432.CCR-1060-02.","journal-title":"Clinical Cancer Research"},{"key":"874_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0960-9776(03)00137-1","volume":"12","author":"CK Osborne","year":"2003","unstructured":"Osborne CK, Schiff R: Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003, 12: 362-367. 10.1016\/S0960-9776(03)00137-1.","journal-title":"Breast"},{"key":"874_CR3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.1991.9.3.371","volume":"9","author":"JC Marsh","year":"1991","unstructured":"Marsh JC, Bertino JR, Katz KH, Davis CA, Durivage HJ, Rome LS, Richards F, Capizzi RL, Farber LR, Pasquale DN, et al: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol. 1991, 9: 371-380.","journal-title":"J Clin Oncol"},{"key":"874_CR4","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1139\/y88-101","volume":"66","author":"DR Wilson","year":"1988","unstructured":"Wilson DR, Honrath U, Sonnenberg H: Interaction of amiloride and hydrochlorothiazide with atrial natriuretic factor in the medullary collecting duct. Can J Physiol Pharmacol. 1988, 66: 648-654. 10.1139\/y88-101.","journal-title":"Can J Physiol Pharmacol"},{"key":"874_CR5","first-page":"1279","volume":"77","author":"J Frank","year":"2008","unstructured":"Frank J: Managing hypertension using combination therapy. American Family Physician. 2008, 77: 1279-1286.","journal-title":"American Family Physician"},{"key":"874_CR6","first-page":"697","volume":"159","author":"R Chan","year":"2008","unstructured":"Chan R, Park KC, Lee MH, Lee ES, Chang SE, Leow YH, Tay YK, Legarda-Montinola F, Tsai RY, Tsai TH, et al: A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008, 159: 697-703.","journal-title":"Br J Dermatol"},{"key":"874_CR7","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1073\/pnas.0500055102","volume":"102","author":"N Agrawal","year":"2005","unstructured":"Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, Chiang AS, Thompson LM, Marsh JL: Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proceedings of the National Academy of Sciences of the United States of America. 2005, 102: 3777-3781. 10.1073\/pnas.0500055102.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"874_CR8","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1002\/pmic.200600119","volume":"6","author":"N Campostrini","year":"2006","unstructured":"Campostrini N, Marimpietri D, Totolo A, Mancone C, Fimia GM, Ponzoni M, Righetti PG: Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line. Proteomics. 2006, 6: 4420-4431. 10.1002\/pmic.200600119.","journal-title":"Proteomics"},{"key":"874_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nbt.1549","volume":"27","author":"J Lehar","year":"2009","unstructured":"Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF, Staunton JE, Jin X, et al: Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nature Biotechnology. 2009, 27: 659-666. 10.1038\/nbt.1549.","journal-title":"Nature Biotechnology"},{"key":"874_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","volume":"12","author":"GR Zimmermann","year":"2007","unstructured":"Zimmermann GR, Lehar J, Keith CT: Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discovery Today. 2007, 12: 34-42. 10.1016\/j.drudis.2006.11.008.","journal-title":"Drug Discovery Today"},{"key":"874_CR11","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1158\/1535-7163.MCT-05-0022","volume":"4","author":"M Pennati","year":"2005","unstructured":"Pennati M, Campbell AJ, Curto M, Binda M, Cheng YZ, Wang LZ, Curtin N, Golding BT, Griffin RJ, Hardcastle IR, et al: Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Molecular Cancer Therapeutics. 2005, 4: 1328-1337. 10.1158\/1535-7163.MCT-05-0022.","journal-title":"Molecular Cancer Therapeutics"},{"key":"874_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/104454601750284117","volume":"11","author":"BR Lewis","year":"2001","unstructured":"Lewis BR, Aoun SL, Bernstein GA, Crow SJ: Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate. Journal of Child and Adolescent Psychopharmacology. 2001, 11: 193-198. 10.1089\/104454601750284117.","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"874_CR13","doi-asserted-by":"publisher","first-page":"i547","DOI":"10.1093\/bioinformatics\/btq382","volume":"26","author":"L Tari","year":"2010","unstructured":"Tari L, Anwar S, Liang S, Cai J, Baral C: Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics. 2010, 26: i547-553. 10.1093\/bioinformatics\/btq382.","journal-title":"Bioinformatics"},{"key":"874_CR14","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1093\/nar\/gkn145","volume":"36","author":"XM Zhao","year":"2008","unstructured":"Zhao XM, Wang RS, Chen L, Aihara K: Uncovering signal transduction networks from high-throughput data by integer linear programming. Nucleic Acids Res. 2008, 36: e48-10.1093\/nar\/gkn145.","journal-title":"Nucleic Acids Res"},{"key":"874_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1142\/S0219720009004138","volume":"7","author":"XM Zhao","year":"2009","unstructured":"Zhao XM, Wang RS, Chen L, Aihara K: Automatic modeling of signaling pathways by network flow model. J Bioinform Comput Biol. 2009, 7: 309-322. 10.1142\/S0219720009004138.","journal-title":"J Bioinform Comput Biol"},{"key":"874_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cell.2010.02.011","volume":"140","author":"N Geva-Zatorsky","year":"2010","unstructured":"Geva-Zatorsky N, Dekel E, Cohen AA, Danon T, Cohen L, Alon U: Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses. Cell. 2010, 140: 643-651. 10.1016\/j.cell.2010.02.011.","journal-title":"Cell"},{"key":"874_CR17","doi-asserted-by":"publisher","first-page":"e1000249","DOI":"10.1371\/journal.pcbi.1000249","volume":"4","author":"D Calzolari","year":"2008","unstructured":"Calzolari D, Bruschi S, Coquin L, Schofield J, Feala JD, Reed JC, McCulloch AD, Paternostro G: Search Algorithms as a Framework for the Optimization of Drug Combinations. Plos Computational Biology. 2008, 4: e1000249-10.1371\/journal.pcbi.1000249.","journal-title":"Plos Computational Biology"},{"key":"874_CR18","doi-asserted-by":"publisher","first-page":"i310","DOI":"10.1093\/bioinformatics\/btr202","volume":"27","author":"G Jin","year":"2011","unstructured":"Jin G, Zhao H, Zhou X, Wong ST: An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data. Bioinformatics. 2011, 27: i310-i316. 10.1093\/bioinformatics\/btr202.","journal-title":"Bioinformatics"},{"issue":"Suppl 2","key":"874_CR19","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1752-0509-4-S2-S7","volume":"4","author":"Z Wu","year":"2010","unstructured":"Wu Z, Zhao XM, Chen L: A systems biology approach to identify effective cocktail drugs. BMC Syst Biol. 2010, 4 (Suppl 2): S7-10.1186\/1752-0509-4-S2-S7.","journal-title":"BMC Syst Biol"},{"key":"874_CR20","doi-asserted-by":"publisher","first-page":"e1002323","DOI":"10.1371\/journal.pcbi.1002323","volume":"7","author":"XM Zhao","year":"2011","unstructured":"Zhao XM, Iskar M, Zeller G, Kuhn M, Noort V, Bork P: Prediction of drug combinations by integrating molecular and pharmacological data. Plos Computational Biology. 2011, 7: e1002323-10.1371\/journal.pcbi.1002323.","journal-title":"Plos Computational Biology"},{"key":"874_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/bioinformatics\/btp697","volume":"26","author":"YB Liu","year":"2010","unstructured":"Liu YB, Hu B, Fu CX, Chen X: DCDB: Drug combination database. Bioinformatics. 2010, 26: 587-588. 10.1093\/bioinformatics\/btp697.","journal-title":"Bioinformatics"},{"key":"874_CR22","doi-asserted-by":"publisher","first-page":"D901","DOI":"10.1093\/nar\/gkm958","volume":"36","author":"DS Wishart","year":"2008","unstructured":"Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M: DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Research. 2008, 36: D901-D906.","journal-title":"Nucleic Acids Research"},{"key":"874_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1137\/S003614450342480","volume":"45","author":"MEJ Newman","year":"2003","unstructured":"Newman MEJ: The structure and function of complex networks. Siam Review. 2003, 45: 167-256. 10.1137\/S003614450342480.","journal-title":"Siam Review"},{"key":"874_CR24","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1126\/science.1065103","volume":"296","author":"S Maslov","year":"2002","unstructured":"Maslov S, Sneppen K: Specificity and stability in topology of protein networks. Science. 2002, 296: 910-913. 10.1126\/science.1065103.","journal-title":"Science"},{"key":"874_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrg1272","volume":"5","author":"AL Barabasi","year":"2004","unstructured":"Barabasi AL, Oltvai ZN: Network biology: understanding the cell's functional organization. Nature Reviews Genetics. 2004, 5: 101-113. 10.1038\/nrg1272.","journal-title":"Nature Reviews Genetics"},{"key":"874_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/archinte.1996.00440030072009","volume":"156","author":"JH MacKay","year":"1996","unstructured":"MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS: Losartan and low-dose hydrochlorothiazide in patients with essential hypertension - A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Archives of Internal Medicine. 1996, 156: 278-285. 10.1001\/archinte.1996.00440030072009.","journal-title":"Archives of Internal Medicine"},{"key":"874_CR27","first-page":"88","volume":"18","author":"PI Salmela","year":"1986","unstructured":"Salmela PI, Juustila H, Kinnunen O, Koistinen P: Comparison of low doses of hydrochlorothiazide plus amiloride and hydrochlorothiazide alone in hypertension in elderly patients. Ann Clin Res. 1986, 18: 88-92.","journal-title":"Ann Clin Res"},{"key":"874_CR28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine. 2005, 353: 1673-1684. 10.1056\/NEJMoa052122.","journal-title":"New England Journal of Medicine"},{"key":"874_CR29","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine. 2005, 353: 1659-1672. 10.1056\/NEJMoa052306.","journal-title":"New England Journal of Medicine"},{"key":"874_CR30","doi-asserted-by":"publisher","first-page":"D412","DOI":"10.1093\/nar\/gkn760","volume":"37","author":"LJ Jensen","year":"2009","unstructured":"Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, et al: STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Research. 2009, 37: D412-D416. 10.1093\/nar\/gkn760.","journal-title":"Nucleic Acids Research"},{"key":"874_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10994-009-5119-5","volume":"77","author":"D Hand","year":"2009","unstructured":"Hand D: Measuring classifier performance: a coherent alternative to the area under the ROC curve. Machine Learning. 2009, 77: 103-123. 10.1007\/s10994-009-5119-5.","journal-title":"Machine Learning"},{"key":"874_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.patrec.2005.10.010","volume":"27","author":"T Fawcett","year":"2006","unstructured":"Fawcett T: An introduction to ROC analysis. Pattern Recognition Letters. 2006, 27: 861-874. 10.1016\/j.patrec.2005.10.010.","journal-title":"Pattern Recognition Letters"},{"key":"874_CR33","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/sj.bjc.6602354","volume":"92","author":"JP Delord","year":"2005","unstructured":"Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic F, Turpin FL, Lokiec F, Lochon I, Chatelut E, Canal P, Guimbaud R, et al: A phase I clinical and pharmacokinetic study of capecitabine (Xeloda[reg]) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer. 2005, 92: 820-826. 10.1038\/sj.bjc.6602354.","journal-title":"Br J Cancer"},{"key":"874_CR34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/sj.bjc.6605261","volume":"101","author":"P Garcia-Alfonso","year":"2009","unstructured":"Garcia-Alfonso P, Munoz-Martin A, Mendez-Urena M, Quiben-Pereira R, Gonzalez-Flores E, Perez-Manga G: Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer. 2009, 101: 1039-1043. 10.1038\/sj.bjc.6605261.","journal-title":"Br J Cancer"},{"key":"874_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10549-007-9610-z","volume":"108","author":"S Dent","year":"2008","unstructured":"Dent S, Messersmith H, Trudeau M: Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Research and Treatment. 2008, 108: 319-331. 10.1007\/s10549-007-9610-z.","journal-title":"Breast Cancer Research and Treatment"},{"key":"874_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10549-007-9590-z","volume":"108","author":"J Chang","year":"2008","unstructured":"Chang J, Makris A, Gutierrez M, Hilsenbeck S, Hackett J, Jeong J, Liu M-L, Baker J, Clark-Langone K, Baehner F, et al: Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Research and Treatment. 2008, 108: 233-240. 10.1007\/s10549-007-9590-z.","journal-title":"Breast Cancer Research and Treatment"},{"key":"874_CR37","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S0305-7372(05)80004-0","volume":"31","author":"C Levy","year":"2005","unstructured":"Levy C, Fumoleau P: Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?. Cancer Treatment Reviews. 2005, 31: S17-S22.","journal-title":"Cancer Treatment Reviews"},{"key":"874_CR38","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics. 2008, 7: 3129-3140. 10.1158\/1535-7163.MCT-08-0013.","journal-title":"Molecular Cancer Therapeutics"},{"key":"874_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1634\/theoncologist.12-4-443","volume":"12","author":"M Los","year":"2007","unstructured":"Los M, Roodhart JML, Voest EE: Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist. 2007, 12: 443-450. 10.1634\/theoncologist.12-4-443.","journal-title":"Oncologist"},{"key":"874_CR40","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1200\/JCO.2007.10.8332","volume":"26","author":"NS Azad","year":"2008","unstructured":"Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, et al: Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. Journal of Clinical Oncology. 2008, 26: 3709-3714. 10.1200\/JCO.2007.10.8332.","journal-title":"Journal of Clinical Oncology"},{"key":"874_CR41","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.ejca.2006.04.004","volume":"42","author":"S Kumar","year":"2006","unstructured":"Kumar S, Rajkumar SV: Thalidomide and lenalidomide in the treatment of multiple myeloma. European Journal of Cancer. 2006, 42: 1612-1622. 10.1016\/j.ejca.2006.04.004.","journal-title":"European Journal of Cancer"},{"key":"874_CR42","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminhematol.2005.10.001","volume":"42","author":"KC Anderson","year":"2005","unstructured":"Anderson KC: Lenalidomide and thalidomide: Mechanisms of action - Similarities and differences. Seminars in Hematology. 2005, 42: S3-S8.","journal-title":"Seminars in Hematology"},{"key":"874_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0306-9877(03)00075-6","volume":"60","author":"DF Horrobin","year":"2003","unstructured":"Horrobin DF: A low toxicity maintenance regime, using eicosapentaenoic acid and readily available drugs, for mantle cell lymphoma and other malignancies with excess cyclin D1 levels. Medical Hypotheses. 2003, 60: 615-623. 10.1016\/S0306-9877(03)00075-6.","journal-title":"Medical Hypotheses"},{"key":"874_CR44","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/10428190802005191","volume":"49","author":"S Vallet","year":"2008","unstructured":"Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC: Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma. 2008, 49: 1238-1245. 10.1080\/10428190802005191.","journal-title":"Leuk Lymphoma"},{"key":"874_CR45","doi-asserted-by":"publisher","first-page":"12579","DOI":"10.1073\/pnas.2132527100","volume":"100","author":"MP Samanta","year":"2003","unstructured":"Samanta MP, Liang S: Predicting protein functions from redundancies in large-scale protein interaction networks. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100: 12579-12583. 10.1073\/pnas.2132527100.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"}],"container-title":["BMC Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-0509-6-S1-S5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:13:10Z","timestamp":1630523590000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsystbiol.biomedcentral.com\/articles\/10.1186\/1752-0509-6-S1-S5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":45,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1186\/1752-0509-6-s1-s5","relation":{},"ISSN":["1752-0509"],"issn-type":[{"value":"1752-0509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"16 July 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"S5"}}